A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab.
Hepatosplenic gamma-delta T-cell lymphoma is a rare, usually fatal lymphoma and available literature on management is sparse. Allografting is probably the only curative option. We describe a further case with a dramatic, though transient response to Fludarabine and Alemtuzumab combination, following a failure of conventional chemotherapy. Given the dreadful prognosis with conventional chemotherapy, it is a regimen worth pursuing as a disease reduction strategy prior to allograft where appropriate.
Department of Clinical Haematology, Aberdeen Royal Infirmary, Aberdeen, UK. sajjanmittal@yahoo.com
S
S
Mittal
B J
BJ
Milner
P W
PW
Johnston
D J
DJ
Culligan
D000293:Adolescent; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000008:administration & dosage / Q000009:adverse effects; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin; D003131:Combined Modality Therapy; D003424:Crohn Disease / Q000150:complications; D003561:Cytarabine; D015251:Epirubicin / Q000008:administration & dosage; D020031:Epstein-Barr Virus Infections / Q000150:complications; D005047:Etoposide / Q000008:administration & dosage; D017809:Fatal Outcome; D016694:Gene Rearrangement, delta-Chain T-Cell Antigen Receptor; D015334:Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008099:Liver / Q000473:pathology*; D016411:Lymphoma, T-Cell, Peripheral / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D008232:Lymphoproliferative Disorders / Q000209:etiology; D008297:Male; D008775:Methylprednisolone; D015649:Pentostatin / Q000627:therapeutic use; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000032:analysis*; D012074:Remission Induction; D013154:Spleen / Q000473:pathology*; D014184:Transplantation, Homologous; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000964:Antimetabolites, Antineoplastic; D007166:Immunosuppressive Agents; D016692:Receptors, Antigen, T-Cell, gamma-delta; D003561:Cytarabine; D015649:Pentostatin; D000074323:Alemtuzumab; D015251:Epirubicin; D005047:Etoposide; D014740:Vidarabine; C024352:fludarabine; D002945:Cisplatin; D007069:Ifosfamide; D008775:Methylprednisolone